Epidemiology and treatment of Merkel cell carcinoma Duprat JP et al. 7. Busse PM, Clark JR, Muse VV, Liu V. Case records of the Massachusetts General Hospital. Case 19-2008. A 63-year-old HIV-positive man with cutaneous Merkel-cell carcinoma. N Engl J Med. 2008;358:2717-23, doi: 10.1056/NEJMc0707784. 8. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096- 100, doi: 10.1126/science.1152586. 9. Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev. 1999;8:153-8. 10. Pectasides D, Pectasides M, Economopoulos T. Merkel cell cancer of the skin. Ann Oncol. 2006;17:1489-95, doi: 10.1093/annonc/mdl050. 11. Kaae J, Hansen AV, Biggar RJ, Boyd HA, Moore PS, Wohlfahrt J, et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst. 2010;102:793-801, doi: 10.1093/jnci/djq120. 12. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63:751-61, doi: 10.1016/j.jaad. 2010.02.056. 13. Gaudin PB, Rosai J. Florid vascular proliferation associated with neural and neuroendocrine neoplasms. A diagnostic clue and potential pitfall. Am J Surg Pathol. 1995;19:642-52, doi: 10.1097/00000478-199506000- 00004. 14. Kukko H, Koljonen V, Lassus P, Tukiainen E, Haglund C, Bohling T. Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma. Anticancer Res. 2007;27:2587-9. 15. Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011;71:1573-83, doi: 10.1158/0008-5472.CAN- 10-3126. 16. Vazmitel M, Michal M, Shelekhova KV, Sima R, Mukensnabl P, Kazakov DV. Vascular changes in merkel cell carcinoma based on a histopatho- logical study of 92 cases. Am J Dermatopathol. 2008;30:106-11, doi: 10. 1097/DAD.0b013e318162eaa2. 17. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500-8, doi: 10.1158/0008-5472.CAN- 05-2925. 18. Jozwiak J, Jozwiak S, Grzela T, Lazarczyk M. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. Neuromolecular Med. 2005;7:287-96, doi: 10.1385/ NMM:7:4:287. 19. Becker JC, Kauczok CS, Ugurel S, Eib S, Brocker EB, Houben R. Merkel cell carcinoma: molecular pathogenesis, clinical features and therapy. J Dtsch Dermatol Ges. 2008;6:709-19, doi: 10.1111/j.1610-0387.2008.06830. x. 20. Jansen B, Heere-Ress E, Schlagbauer-Wadl H, Halaschek-Wiener J, Waltering S, Moll I, et al. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. J Mol Med 1999;77:792-7, doi: 10.1007/s001099900052. 21. Boratynska M, Watorek E, Smolska D, Patrzalek D, Klinger M. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc. 2007;39:2736-9, doi: 10.1016/j.transpro- ceed.2007.08.078. 22. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-35, doi: 10.1038/nm0202-128. 23. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581-9, doi: 10.1681/ASN.2005090993. 24. Krasagakis K, Fragiadaki I, Metaxari M, Kruger-Krasagakis S, Tzanakakis GN, Stathopoulos EN, et al. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro. J Cell Physiol. 2011;226:1099-109, doi: 10.1002/jcp.22431. 25. Eng TY, Boersma MG, Fuller CD, Cavanaugh SX, Valenzuela F, Herman TS. Treatment of merkel cell carcinoma. Am J Clin Oncol. 2004;27:510-5, doi: 10.1097/01.coc.0000135567.62750.f4. 26. Bobos M, Hytiroglou P, Kostopoulos I, Karkavelas G, Papadimitriou CS. Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung. Am J Dermatopathol. 2006;28:99-104, doi: 10.1097/01.dad.0000183701.67366.c7. 27. Yiengpruksawan A, Coit DG, Thaler HT, Urmacher C, Knapper WK. Merkel cell carcinoma. Prognosis and management. Arch Surg. 1991;126:1514-9. 28. Allen PJ, Zhang ZF, Coit DG. Surgical management of Merkel cell carcinoma. Ann Surg. 1999;229:97-105, doi: 10.1097/00000658-199901000- 00013. 29. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23:2300-9, doi: 10.1200/JCO.2005.02.329. 1822 CLINICS 2011;66(10):1817-1823 30. Pitale M, Sessions RB, Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope. 1992;102:244-9, doi: 10.1288/00005537-199203000-00003. 31. Hitchcock CL, Bland KI, Laney RG, 3rd, Franzini D, Harris B, Copeland EM, 3rd. Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann Surg. 1988;207:201-7, doi: 10. 1097/00000658-198802000-00015. 32. Cotlar AM, Gates JO, Gibbs FA, Jr. Merkel cell carcinoma: combined surgery and radiation therapy. Am Surg. 1986;52:159-64. 33. Boyle F, Pendlebury S, Bell D. Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinoma. Int J Radiat Oncol Biol Phys. 1995;31:315-23, doi: 10.1016/ 0360-3016(93)E0110-R. 34. Queirolo P, Gipponi M, Peressini A, Disomma CF, Vecchio S, Raposio E, et al. Merkel cell carcinoma of the skin. Treatment of primary, recurrent, and metastatic disease: review of clinical cases. Anticancer Res. 1997;17:673-7. 35. Westgate SJ. Radiation therapy for skin tumors. Otolaryngol Clin North Am. 1993;26:295-309. 36. Bichakjian CK, Lowe L, Lao CD, Sandler HM, Bradford CR, Johnson TM, et al. Merkel cell carcinoma: critical review with guidelines for multi- disciplinary management. Cancer. 2007;110:1-12, doi: 10.1002/cncr. 22765. 37. Sibley RK, Dehner LP, Rosai J. Primary neuroendocrine (Merkel cell?) carcinoma of the skin. I. A clinicopathologic and ultrastructural study of 43 cases.Am J Surg Pathol. 1985;9:95-108, doi: 10.1097/00000478- 198502000-00004. 38. Messina JL, Reintgen DS, Cruse CW, Rappaport DP, Berman C, Fenske NA, et al. Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. Ann Surg Oncol. 1997;4:389-95, doi: 10.1007/BF02305551. 39. Edge SB, Byrd DR, Compton CC. 30 Merkel Cell Carcinoma. In: Edge SB, Byrd DR, Compton CC, editors. AJCC CANCER STAGING MANUAL- Seventh Edition. Seventh ed. Chicago: Springer New York Dordrecht Heildelberg London. 2010;315-9. 40. Boyer JD, Zitelli JA, Brodland DG, D’Angelo G. Local control of primary Merkel cell carcinoma: review of 45 cases treated with Mohs micro- graphic surgery with and without adjuvant radiation. J Am Acad Dermatol. 2002;47:885-92, doi: 10.1067/mjd.2002.125083. 41. Jabbour J, Cumming R, Scolyer RA, Hruby G, Thompson JF, Lee S. Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early- stage disease—results from a review of 82 consecutive cases diagnosed between 1992 and 2004. Ann Surg Oncol. 2007;14:1943-52, doi: 10.1245/ s10434-006-9327-y. 42. Gonzalez RJ, Padhya TA, Cherpelis BS, Prince MD, Aya-Ay ML, Sondak VK, et al. The surgical management of primary and metastatic Merkel cell carcinoma. Curr Probl Cancer. 2010;34:77-96, doi: 10.1016/j.curr- problcancer.2010.02.003. 43. Warner RE, Quinn MJ, Hruby G, Scolyer RA, Uren RF, Thompson JF. Management of merkel cell carcinoma: the roles of lymphoscintigraphy, sentinel lymph node biopsy and adjuvant radiotherapy. Ann Surg Oncol. 2008;15:2509-18, doi: 10.1245/s10434-008-9983-1. 44. Fenig E, Lurie H, Klein B, Sulkes A. The treatment of advanced Merkel cell carcinoma. A multimodality chemotherapy and radiation therapy treatment approach. J Dermatol Surg Oncol. 1993;19:860-4. 45. Gollard R, Weber R, Kosty MP, Greenway HT, Massullo V, Humberson C. Merkel cell carcinoma: review of 22 cases with surgical, pathologic, and therapeutic considerations. Cancer. 2000;88:1842-51, doi: 10.1002/ (SICI)1097-0142(20000415)88:8,1842::AID-CNCR13.3.0.CO;2-P. 46. Lewis KG, Weinstock MA, Weaver AL, Otley CC. Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol. 2006;142:693-700, doi: 10.1001/archderm.142.6.693. 47. Gillenwater AM, Hessel AC, Morrison WH, Burgess M, Silva EG, Roberts D, et al. Merkel cell carcinoma of the head and neck: effect of surgical excision and radiation on recurrence and survival. Arch Otolaryngol Head Neck Surg. 2001;127:149-54. 48. Meeuwissen JA, Bourne RG, Kearsley JH. The importance of post- operative radiation therapy in the treatment of Merkel cell carcinoma. Int J Radiat Oncol Biol Phys. 1995;31:325-31, doi: 10.1016/0360- 3016(94)E0145-A. 49. Rao NG. Review of the role of radiation therapy in the management of Merkel cell carcinoma. Curr Probl Cancer. 2010;34:108-17, doi: 10.1016/j. currproblcancer.2010.01.005. 50. Mortier L, Mirabel X, Fournier C, Piette F, Lartigau E. Radiotherapy alone for primary Merkel cell carcinoma. Arch Dermatol. 2003;139:1587- 90, doi: 10.1001/archderm.139.12.1587. 51. Veness M, Foote M, Gebski V, Poulsen M. The role of radiotherapy alone in patients with merkel cell carcinoma: reporting the Australian experience of 43 patients. Int J Radiat Oncol Biol Phys. 2010;78:703-9, doi: 10.1016/j.ijrobp.2009.08.011. 52. Hui AC, Stillie AL, Seel M, Ainslie J. Merkel Cell Carcinoma: 27-Year Experience at the Peter MacCallum Cancer Centre. Int J Radiat Oncol